NANOBIOTIX (NANO.PA)

FR0011341205 - Common Stock

5.25  +0.05 (+1.06%)

Fundamental Rating

1

Taking everything into account, NANO scores 1 out of 10 in our fundamental rating. NANO was compared to 79 industry peers in the Biotechnology industry. NANO has a bad profitability rating. Also its financial health evaluation is rather negative. NANO does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

NANO had negative earnings in the past year.
In the past year NANO has reported a negative cash flow from operations.
NANO had negative earnings in each of the past 5 years.
NANO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -145.48%, NANO is not doing good in the industry: 82.43% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -145.48%
ROE N/A
ROIC N/A
ROA(3y)-55.56%
ROA(5y)-64.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NANO remains at a similar level compared to 1 year ago.
NANO has more shares outstanding than it did 5 years ago.
NANO has a worse debt/assets ratio than last year.

2.2 Solvency

NANO has an Altman-Z score of -13.47. This is a bad value and indicates that NANO is not financially healthy and even has some risk of bankruptcy.
NANO has a worse Altman-Z score (-13.47) than 89.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.47
ROIC/WACCN/A
WACC6.62%

2.3 Liquidity

NANO has a Current Ratio of 0.67. This is a bad value and indicates that NANO is not financially healthy enough and could expect problems in meeting its short term obligations.
NANO has a worse Current ratio (0.67) than 90.54% of its industry peers.
A Quick Ratio of 0.67 indicates that NANO may have some problems paying its short term obligations.
NANO's Quick ratio of 0.67 is on the low side compared to the rest of the industry. NANO is outperformed by 90.54% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.67

More info and screens

3

3. Growth

3.1 Past

The earnings per share for NANO have decreased strongly by -36.50% in the last year.
Looking at the last year, NANO shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-36.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-5.26%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 9.01% on average over the next years. This is quite good.
The Revenue is expected to grow by 60.10% on average over the next years. This is a very strong growth
EPS Next Y51.04%
EPS Next 2Y19.91%
EPS Next 3Y7.71%
EPS Next 5Y9.01%
Revenue Next Year1118.18%
Revenue Next 2Y354.47%
Revenue Next 3Y145.02%
Revenue Next 5Y60.1%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NANO. In the last year negative earnings were reported.
Also next year NANO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.91%
EPS Next 3Y7.71%

More info and screens

0

5. Dividend

5.1 Amount

NANO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX

EPA:NANO (4/19/2024, 7:00:00 PM)

5.25

+0.05 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap247.33M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -145.48%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.67
Quick Ratio 0.67
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-36.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y51.04%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y